NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-02575-01

Docket or Reference number: 030-02449

Amendment No. 50

Muhlenberg Hospital
Randolph Road
Plainfield, New Jersey 07061

In accordance with letters dated July 3, 1985 and September 10, 1985, License Number 20-02575-01 is amended as follows:

Items 6., 7., 8., and 9., are amended to read:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 1300 millicuries total for sources authorized in Subitem 6.E.
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 3 millicuries of each byproduct material authorized in Subitem 6.F.
G. Xenon 133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	G. 150 millicuries

1/1
ML10

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 29-02575-01
Docket or Reference number 030-02449
Amendment No. 50

(continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
H. Americium 241	H. Sealed source (Amersham Model No. AMC.24)	H. Two sources not to exceed 14 millicuries each
I. Americium 241	I. Sealed sources (Amersham Model AMC-D1)	I. Two sources, not to exceed 45 millicuries each
J. Iodine 125	J. Sealed sources (AECL-CP Models C-235, C-236 or Amersham Model IMC-4040)	J. Two sources, not to exceed 400 millicuries each
K. Iodine 125	K. Sealed sources (Amersham Model IMC-129)	K. Two sources not to exceed 200 millicuries each
L. Iodine 125	L. Sealed sources (Amersham Model IMC 4052)	L. Two sources not to exceed 100 millicuries each
M. Gadolinium 153	M. Sealed sources (Gulf Nuclear Model GD-1)	M. Two sources, not to exceed 1.0 curie each
N. Gadolinium 153	N. Sealed sources (GI-Series)	N. Two sources, not to exceed 1.5 curies
O. Iodine 125	O. Sealed sources (AECL Models C-235 C-324 or Amersham Model IMC-PC2)	O. Two sources, not to exceed 300 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. In vitro studies.
G. Blood flow and pulmonary function studies.
H. For use in Searle Analytic Model SS-10244 Anatomical Marker.
I., J., K., and L. For use in a Norland Model 2740/2780 bone mineral analyzer.
M. For use in a Norland Model 2600 bone mineral analyzer.
N. For use in a Lunar Radiation Corporation Model DP3 bone mineral analyzer.
O. For use in Lunar Radiation Corporation Model SP2 bone mineral analyzer.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 29-02575-01
Docket or Reference number 030-02449
Amendment No. 50

(continued)

Condition 18. is amended to read:

18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated January 15, 1979; letters dated December 20, 1979, March 26, 1980, May 5, 1982, October 11, 1982, December 3, 1982, November 23, 1983, December 11, 1984; application dated April 29, 1985 and letters dated May 24, 1985, July 3, 1985 and September 5, 1985; and Model ALARA Program contained in Appendix O of Regulatory Guide 10.8 (Rev. 1), "Guide for the Preparation of Applications for Medical Programs", October 1980; and Model ALARA Program contained in Appendix O of Regulatory Guide 10.8 (Rev. 1), "Guide for the Preparation of Applications for Medical Programs", October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date OCT 02 1985

By Original Signed By:
Jenny M. Johansen
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406